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Clinical Observations 
 
A Clinical Study on the Effects and Mechanism of Xuebijing Injection  
(㸔ᖙޔ⊼ᇘ⎆) in Severe Pneumonia Patients 
 
QI Fei 唤㧆 1, LIANG Zhi-xin ṕᖫᮄ 1, SHE Dan-yang ԬЍ䰇 1, YAN Guang-Tao 买ܝ⍯ 2 , 
and CHEN Liang-an 䰜㡃ᅝ 1 
 
 
Objective: To observe the effects of Xuebijing Injection (㸔ᖙޔ⊼ᇘ⎆) in patients with severe pneumonia, and to 
explore the mechanism.  
Methods: Eighty cases of severe pneumonia are randomly assigned to the Xuebijing treatment (forty cases) and the 
control group (forty cases), with the same routine therapy provided in both groups. Clinical effective rates, 
inflammatory factors and organ function were observed in both groups.  
Results: The effective rate was higher in Xuebijing group than that of the control group (80.0% vs. 67.5%, P<0.05). 
As compared with the control group, the LDH, Į1-AG, Į1-AT levels and the peak body temperature decreased 
markedly with the Xuebijing treatment going, and the secretion of TNF-Į, IL-6, IL-8 was suppressed in Xuebijing 
group; but no significant difference was found in leptin level.  
Conclusion: Xuebijing Injection may show a protective effect in patients with severe pneumonia. The mechanism 
is possibly with the decreased secretion of TNF-Į, IL-6, and IL-8. 
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Great progress has been achieved in antimicrobial 
therapeutics in recent years, yet severe pneumonia 
remains a major challenge in clinical treatment of 
pulmonary infection. The ageing society, increasing 
immuno-impaired hosts, diversifying pathogens as well 
as the rising drug resistance and other factors have lead 
to a rise of morbidity and mortality of severe pneumonia.    
Xuebijing Injection (㸔ᖙޔ⊼ᇘ⎆ XBJ) is epurated 
from Chinese herbs, with satisfactory antiendotoxin and 
anti-inflammatory effects shown in clinical trials.1,2 The 
present study was designed to observe the effects of 
Xuebijing in patients with severe pneumonia and the 
influences on white blood cell (WBC), lactate 
dehydrogenase (LDH), peak body temperature (Tmax) 
and acute phase reactants, and to explore the 
mechanism through detection of the cytokines. 
METHODS 
General Materials 
The study evaluated the data in 80 patients with a 
confirmed diagnosis of severe pneumonia admitted at 
Respiratory Intensive Care Unit of PLA General Hospital 
from September 2007 to December 2009. The study was 
carried out with the approval from the Medical Ethics 
Committee of Chinese PLA General Hospital. Informed 
consent was obtained from all the study subjects. 
According to the definition formulated by American 
Thoracic Society in 2007, the patients with a past history 
of severe hepatic or renal dysfunction, rheumatic 
diseases, pulmonary fibrosis, tuberculosis or severe 
malnutrition were excluded. These 80 patients were  
assigned with double-blind randomized clinical study to 
the Xuebijing treatment group (forty cases) and the 
control group (forty cases). 
The data were comparable between the two groups with 
no significant differences in gender, age, duration of 
illness, clinical symptoms and signs and in the Acute 
Physiology and Chronic Health Evaluation Ċ score as is 
presented in Table 1. 1 
Treatment 
Routine anti-microbial and sputum elimination agents 
were given to patients of both the two groups. Xuebijing 
Injection produced by Tianjin Hongri Pharmaceuticals 
Co. Ltd. was additionally used in the Xuebijing treatment, 
50 ml of Xuebijing Injection with 100 ml of normal 
saline administered through intravenous drip twice a day. 
In order to enhance the therapeutic effects, Xuebijing 
Injection was given after the use of antibiotics. The 
treatment course was 14 days for both the two groups. 
Criteria for Therapeutic Effects 
The therapeutic effect is excellent if the symptoms of 
fever, cough, expectoration and dyspnea disappear, moist 
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and dry rales of both lungs vanish, and the chest X ray 
shows normal in 14 days after the treatment. The effect 
is moderate if the above symptoms alleviate, moist and 
dry rales reduce, and the chest X-ray shows partial 
resorption of inflammation. The treatment is ineffective 
if the symptoms and signs are not improved or even 
detoriated, and the chest X-ray reveals no resorption in 
14 days. 
Table 1. Baseline characteristics of the 80 patients 
involved in the study 
Group Control 
group 
(n=40) 
Xuebijing 
group 
(n=40) 
Male 23 25 Gender 
Female 17 15 
65years 21 19 Age 
>65years 19 21 
30 days 28 24 Duration  
 >30 days 12 16 
Type 2 diabetes 
mellitus 
3 5 
Coronary heart 
disease 
5 5 
Hypertension  9 6 
Cerebralvascular 
disease 
3 6 
Tracheotomy 3 4 
Comorbidities 
Mechanical 
ventilation   
4 2 
Ǻ-lactams/enzyme 
inhibitors 
16 20 
Linezolid 7 5 
Quinolinones 14 15 
Carbapenem 12 11 
Glycopeptides 2 1 
Antibiotics 
Fluconazole   6 8 
25   22 19 APACHEĊ 
>25 18 21 
Indexes Observed 
The peak body temperature, WBC count, neutrophils (N), 
and the levels of serum LDH, C-reactive protein (CRP) 
were measured in patients of both the groups at baseline 
and on the 3rd, 7th and 14th day of treatment. By means 
of the enzyme linked immunosorbent assay, the levels of 
Į1-acid glycoprotein (Į1-AG), Į1-antitrypsin (Į1-AT), 
interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor 
necrosis factor (TNF-Į) were detected, and the level of 
leptin was determined by radioimmunoassay. 
Statistical Analysis 
The Stata software7.0 was used for statistical analysis. 
Parametric statistics, including student paired t-test and 
one-factor analysis of variance, is performed if the data 
accords with normal distribution and the variance is of 
homogeneity. Otherwise, nonparameter test, known as 
rank sum test, is performed instead. The data are expressed 
as mean ± standard deviation, and P<0.05 is considered 
significant. 
RESULTS 
Comparison of the Therapeutic Effects 
1. Effective rates in the two groups 
As shown in Table 2, the total effective rate in Xuebijing 
treatment group was markedly higher than that of the 
control group (P<0.05). 
2. Comparison of WBC, LDH and the peak body 
temperature  
As compared with the baseline, the WBC, LDH and peak 
body temperature showed a markedly reducing tendency 
in both the groups (Table 3). WBC in both groups turned 
to normal on the 7th day. On the 14th day, the LDH level 
was significantly decreased in the Xuebijing treatment 
group, but no significant difference was found in the 
control group. The peak body temperature in the 
Xuebijing treatment group fell down to normal on the 
3rd day, but it remained unchanged in patients of the 
control group on the 3rd day. 
3. Comparison of the acute phase reactant levels (Table 
4) 
In patients of both groups, the serum CRP, Į1-AG levels 
showed an obviously decreasing tendency as the 
treatment went on. On the 3rd day, CRP and Į1-AG in 
the Xuebijing treatment group were significantly 
decreased, and lower than those in the control group 
(P<0.05). In the control group, the concentration of 
Į1-AT appeared to be ascending but consequently 
descending, whereas a notable decrease of Į1-AT was 
found in the Xuebijing treatment group (P<0.05). 
Generally speaking, as compared with the control group, 
the serum CRP, Į1-AG and Į1-AT levels in patients of 
the Xuebijing treatment group were decreased earlier and 
more obviously (P<0.05). 
Table 2. Comparison of the effective rates in the two groups of patients with severe pneumonia  
Group  Cases Excellent Moderate Inefficiant Total effective rate (%) 
Xuebijing 40 15 17 8 80.0* 
Control  40 12 15 13 67.5 
Note: As compared with the control group, *P<0.05. 
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Table 3. Comparison of WBC, N, LDH and the peak body temperature in the two groups of patients with severe 
pneumonia (cases=40) 
Item Group Baseline 3rd day 7th day 14th day 
XBJ 15.90±8.50 10.90±5.40  8.40±3.60*  5.70±1.90*# WBC (109/L) 
Control 13.10±6.00 10.50±4.50  9.30±4.10*  8.10±2.50* 
XBJ  0.81±0.13  0.80±0.11 0.82±0.11 0.75±0.13 N (%) 
Control  0.82±0.10  0.78±0.13 0.80±0.11  0.72±0.18* 
XBJ  444.00±354.00  413.00±185.00 392.00±229.00 253.00±89.00* LDH (U/L) 
Control  316.00±210.00  307.00±177.00 283.00±134.00 238.00±119.00 
XBJ 37.60±1.10  36.90±0.70* 36.90±0.60* 36.80±0.80* Tmax (ć) 
Control 37.50±1.20 37.10±0.80 36.90±0.70 36.80±0.80 
Notes: *P<0.05, as compared with the baseline; #P<0.05 as compared with the control group. 
Changes in the Levels of Cytokines 
As shown in Table 5 the serum IL-6 level was reduced 
in both the two groups as the treatment went on. On the 
3rd day, the IL-6 level in patients of the Xuebijing 
treatment group was obviously decreased as compared 
with the control group (P<0.05). The serum TNF-Į and 
IL-8 level were elevated the treatment went on; whereas 
no significant changes were observed in Xuebijing 
group, TNF-Į and IL-8 were markedly lower than the 
control group respectively on the 7th day and the 14th 
day. The leptin level showed no obvious change as 
compared with the baseline in both the groups.
Table 4. Comparison of the acute phase reactant levels in the two groups of patients with severe pneumonia (cases=40) 
Marker Group    Baseline 3rd day 7th day 14th day 
CRP 
(mg/dL) 
XBJ 
Control 
 13.63±8.95 
 10.35±6.40 
    6.08±4.01*# 
 10.16±4.15 
6.06±4.22* 
6.06±4.22* 
4.69±3.82* 
4.69±3.82* 
a1-AG 
(ug/mL) 
XBJ 
Control 
 583.00±195.5 
591.90±92.8 
    464.90±113.00*# 
  567.10±128.10 
345.60±59.10*# 
437.30±111.10* 
353.00±99.90* 
330.80±95.40* 
a1-AT 
(mg/mL) 
XBJ 
Control 
 2048.00±610.90 
  1946.00±1232.00 
   2005.00±676.00*# 
   2826.00±1238.00* 
1216.00±506.00*# 
2108.00±929.40 
  730.00±212.70*# 
 1633.00±746.60* 
Notes: *P<0.05, as compared with the baseline; #P<0.05, as compared with the control group. 
Table 5. Comparison of the cytokine levels (IL-6, IL-8, TNF-a, Leptin) of patients with severe pneumonia 
Marker Group    Baseline 3rd day 7th day 14th day 
IL-6 
(ng/mL 
XBJ 
Control 
 0.04±0.01 
 0.03±0.02 
   0.02±0.01*# 
 0.03±0.01 
 0.02±0.00* 
 0.02±0.01* 
 0.02±0.01* 
 0.02±0.01* 
IL-8 
(ng/mL) 
XBJ 
Control 
 0.32±0.12 
 0.31±0.18 
 0.31±0.11 
 0.24±0.15 
0.32±0.18 
 0.48±0.46* 
 0.32±0.13# 
 0.47±0.22* 
TNF-a 
(pg/mL) 
XBJ 
Control 
20.05±9.63 
21.71±7.65 
 22.91±11.29 
 29.72±19.06 
 20.73±11.32# 
 32.49±16.71* 
21.97±11.14 
30.67±13.19 
Leptin 
(ng/mL) 
XBJ 
Control 
10.15±6.31 
10.19±6.63 
10.06±9.00 
13.49±6.65 
11.40±8.22 
11.83±4.89 
13.01±9.86 
12.62±8.89 
Notes: *P<0.05, as compared with baseline; #P<0.05, as compared with the control group. 
DISCUSSION 
The pathogenesis of severe pneumonia is related with 
infection, toxin and the immunological factors, which 
consequently cause damage to the lung tissues. Among 
these factors, bacterial infection is the main cause for 
deterioration of pneumonia, but the use of antibiotics 
alone may not show good results. Some medical 
literature have reported that the combined use of herbal 
medicines for clearing the toxic heat, and expelling the 
sputum may help alleviate the stress reaction, accelerate 
the toxin elimination, and improve the respiratory 
function. Xuebijing Injection is a compound preparation 
of Chinese medicine with the efficacy of activating blood 
circulation to remove blood stasis, cooling the blood and 
clearing the toxic heat, which is composed of Chishao 
(Radix Paeoniae Rubra), Danggui (Radix Angelica 
Sinensis), Chuanxiong (Rhizoma Chuanxiong), Honghua 
(Flos Carthami), and Danshen (Radix Salviae 
Miltiorrhizae). 
The present study shows that the use of antibiotics in 
combination with Xuebijing injection can notably 
decrease the serum LDH level, lower the daily peak body 
temperature, decline the acute phase reactants (CRP, 
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Į1-AG and Į1-AT), and enhance the total effective rate in 
severe pneumonia patients. The secretion of TNF-Į, IL-6 
and IL-8 in Xuebijing-treated patients was obviously 
suppressed as compared with the control group, but with 
no significant influence on the release of leptin. The 
main pathogenic bacteria in severe pneumonia are Gram 
negative, like Pseudomonas aeruginosa, Klebsiella 
pneumoniae and Escherichia coli, etc. Lipopo- 
lysaccharide (LPS), a bioactive substance, exists in the 
adventitia of cell wall of the Gram negative bacterial, 
which is the main inducing substance for systemic 
inflammatory response syndrome (SIRS) and sepsis.3,4 
Many researches have demonstrated that antibiotics can 
drive releasing of LPS while killing the bacteria, and 
LPS may consequently stimulate the macrophages to 
produce more inflammatory mediators, leading to 
deterioration of bacterial infection, or even SIRS and/or 
sepsis.5,6 Among the inflammatory factors, TNF-Į, IL-6 
and IL-8 are the most influential, because they take part 
in the initial onset of SIRS, known as the pre- 
inflammatory mediators; Stimulate to produce more 
secondary inflammatory mediators, and induce the 
synthesis of acute phase reactants like CRP, Į1-AG and 
Į1-AT in the liver. This study showed that secretion of 
TNF-Į, IL-6 and IL-8 was suppressed on the 3rd, 7th and 
14th day after Xuebijing treatment, indicating that 
Xuebijing Injection may extert anti-endotoxin effects by 
blocking the uncontrolled release of endogenic 
inflammatory mediators like TNF-Į, IL-6 and IL-8; as a 
result, the vacious cycle of inflammation onset is 
interrupted, the overactive inflammatory reactions are 
suppressed, the development of SIRS is blocked; 
meanwhile, the acute phase reactants are reduced, and 
the clinical symptoms are relieved, which conform to the 
results of many studies reported both at home and 
abroad.7,8 Leptin is a protein product encoded by fat gene. 
It has the effects on body weight regulatory circuit and 
feedback regulation of energy metabolics, it can also act 
as a cytokine to induce generation, differentiation and 
enhancement of hematopoietic cells, and provide 
monocytes with nutrition, enhance the generation and 
phagocytosis actions of mononuclear macrophages, 
stimulate the secretion of pre-inflammatory and anti- 
inflammatory substances in monocytes, activate the 
vascular regeneration, and strengthen the body 
resistance.9 Through observation of the influence of 
Xuebijing on leptin releasing, the study tries to explore 
whether the effect of Xuebijing is related with the 
enhancement or inhibition of leptin release. The results 
from the present study shows that Xuebijing has no 
significant influence on leptin release, possibly the 
secretion and regulation of leptin are influenced by lots 
of factors, among which the body weight and insulin 
level are the key factors.  
To sum up, Xuebijing Injection can effectively regulate 
the inflammatory factors, alleviate the symptoms and 
various inflammation reactions in severe pneumonia, 
without obvious adverse side effects on the organ 
functions, and biochemical indexes. 
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